title: Mirtazapine substitution in SSRI-induced sexual dysfunction.
abstract: BACKGROUND
  Sexual side effects are a common and bothersome reaction to selective serotonin reuptake inhibitors (SSRIs), frequently leading to cessation of treatment. Mirtazapine, an alpha2-adrenoceptor and serotonin-2/3 receptor antagonist, appears to cause few sexual problems.
  
  
  METHODS
  Nineteen patients (12 women and 7 men), with SSRI-induced sexual dysfunction who were in remission from major depressive disorder (total Hamilton Rating Scale for Depression [HAM-D] score < or = 10), were switched to open-label mirtazapine for up to 6 weeks. Mirtazapine was titrated from 7.5 mg to 45 mg daily, as tolerated. Sexual functioning was measured weekly with the Arizona Sexual Experiences Scale (ASEX), and depression was measured weekly with the HAM-D.
  
  
  RESULTS
  Eleven patients (58%) had a return of normal sexual functioning (mean +/- SD ASEX score = 12+/-3), and another 2 (11%) reported significant improvement in sexual functioning (mean ASEX score reduced from 24+/-1 to 20+/-0). All nineteen patients maintained their antidepressant response (HAM-D score after 6 weeks of mirtazapine = 6+/-3). The most commonly reported side effects (using moderate/severe rating on a symptom checklist) were initial sedation (N = 3), irritability (N = 6), and muscle soreness and stiffness (N = 3). Weight gain of 10 to 20 lb (4.5-9 kg) was seen in 3 patients (2 women and 1 man).
  
  
  CONCLUSIONS
  Mirtazapine is an effective antidepressant for many patients experiencing SSRI-induced sexual dysfunction.
authors.affiliation: Department of Psychiatry, The University of Arizona Health Services Center, Tucson, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Gelenberg
authors.forename: C
authors.initials: C
authors.lastname: McGahuey
authors.forename: C
authors.initials: C
authors.lastname: Laukes
authors.forename: G
authors.initials: G
authors.lastname: Okayli
authors.forename: F
authors.initials: F
authors.lastname: Moreno
authors.forename: L
authors.initials: L
authors.lastname: Zentner
authors.forename: P
authors.initials: P
authors.lastname: Delgado
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D007508:Irritable Mood; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D009135:Muscular Diseases / Q000139:chemically induced; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index; D012725:Sexual Behavior / Q000187:drug effects / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000517:prevention & control*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D000317:Adrenergic alpha-Antagonists; D008803:Mianserin; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors